Interviews on biotechnology

Interview 12 Feb 2018

MorphoSys’ CEO Tells Us What’s Next for Europe’s Antibody Expert

After 25 years, MorphoSys finally got over the line in 2017 with the FDA approval of its first antibody. CEO Simon Moroney tells us how the company hopes to build on its recent success. It may have started out as a tech provider, but MorphoSys now stands as one of the leading German biotechs, specializing […]

February 12, 2018 - 8 minutesmins - By Alex Dale

Interview 7 Feb 2018

Hookipa CEO “Sleeps Quite Well at Night” with €50M Cash Pile and Cancer Vaccine Progress

Did you miss us in Vienna? Here’s the first of our two interviews from the Refresh meetup last month: Jörn Aldag, CEO of Hookipa, talked to us about the importance of a sound financial strategy and where cancer vaccines are on the hype curve. Jörn Aldag has had quite a career. His first position as […]

February 7, 2018 - 4 minutesmins - By Evelyn Warner

Interview 29 Jan 2018

Meet the CEO of the Other Big Biotech Acquisition Target in 2017

Christian Schetter’s company, Rigontec, was acquired by MSD last year for nearly half a billion euro. How did he and the company do it, with only one early-stage candidate? There were exactly two notable biotech acquisitions in Europe last year: Actelion and a smaller startup based in Munich called Rigontec, which had an RNA candidate […]

January 29, 2018 - 9 minutesmins - By Evelyn Warner

Interview 22 Jan 2018

Bravo! An Interview with the CEO of Takeda’s Recent Cell Therapy Target

I sat down with Eduardo Bravo, CEO of TiGenix, to talk about the technology that made his company so attractive to the pharma giant. After beginning his career in big pharma, Eduardo Bravo took the plunge into biotech in 2005 when he saw the opportunity for a breakthrough therapy at a small Spanish biotech called […]

January 22, 2018 - 6 minutesmins - By Evelyn Warner

alzheimers disease acimmune andrea pfeifer 1

Interview 8 Jan 2018

Meet the Swiss CEO Pulling Out All the Stops Against Alzheimer’s Disease

Efforts to treat Alzheimer’s Disease have been hit with failure after failure in the last year or so. Andrea Pfeifer, co-founder and CEO of AC Immune, told me about how her company hopes to pull off a win. Andrea Pfeifer started out as toxicologist in oncology before she moved into entrepreneurship. She left Germany after […]

January 8, 2018 - 8 minutesmins - By Evelyn Warner

Interview 11 Dec 2017

Edwin Moses on how Ablynx has made it to the top of European biotech

Ablynx CEO Edwin Moses discusses the technology and strategy that has led its company to join the ranks of the biggest European biotechs. Ablynx, based in Belgium, has just recently joined the European billion-euro biotech club with a market cap of €1.45Bn. With positive Phase III results for its lead compound and a $230M (€195M) […]

December 11, 2017 - 8 minutesmins - By Clara Rodríguez Fernández

Interview 4 Dec 2017

Meet the CEO Leading Italy’s Charge to Become a Major Biotech Player

Riccardo Palmisano is CEO of MolMed, the most important Italian biotech, which focuses on gene and cell therapies. We chatted about the company, which hopes to give the cancer therapies field a boost. You may have come across MolMed before, possibly in our recent piece on the top biotechs in Milan. The company was founded […]

December 4, 2017 - 7 minutesmins - By Alex Dale

Portugal Ventures Ricardo Perdigao Henriques

Interview 29 Nov 2017

What’s Going on in the Biotech Ecosystem of Portugal?

The biotech ecosystem in Portugal is rapidly growing. Ricardo Perdigao, Investment Manager at Portugal Ventures, discusses the country’s potential in this field. Portugal has seen the number of life sciences startups triple between 2008 to 2015. A study by Portugal Ventures links this growth to a better funding environment and to researchers being more aware that […]

November 29, 2017 - 3 minutesmins - By External Contributor

Interview 27 Nov 2017

A First Treatment for Hearing Loss, Tinnitus and Vertigo? Meet the Man Behind It

Thomas Meyer, CEO of Auris Medical, discusses how biotech can finally bring solutions to those who live with hearing loss, tinnitus and vertigo. Thomas Meyer is at the forefront of a wave of drugs that could, for the first time, show efficacy in treating common hearing disorders. In 2003, he founded Auris Medical to address […]

November 27, 2017 - 10 minutesmins - By Clara Rodríguez Fernández

Interview 20 Nov 2017

Thinking of Leaving Academia? Read this VC Partner’s Story

Anne Portwich, Partner at venture capital firm LSP, told me about her career path and how to succeed in the life science industry. Anne Portwich became the first woman partner at LSP in 2011. The fund has raised more than $1B since it was founded more than 25 years ago, and the cash goes mainly to […]

November 20, 2017 - 9 minutesmins - By Evelyn Warner

Interview 16 Nov 2017

Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics

Tusk Therapeutics is developing antibodies to ignite the immune system response against cancer. We spoke with CEO Luc Dochez about Tusk and the oncology field. Tusk Therapeutics, based just north of London, focuses on therapeutic antibodies to boost the immune system in the fight against cancer. The company has been developing a number of candidates […]

November 16, 2017 - 6 minutesmins - By Alex Dale

topas therapeutics timm jessen interview

Interview 15 Nov 2017

Therapeutic Nanoparticle Companies Are Rare: Meet the CEO of One of Them

In our last BIO Europe interview, I caught up with CEO Timm Jessen of Topas Therapeutics to hear about the company’s nanoparticles. Founded in 2013 as a spinout from Evotec, Topas Therapeutics is developing nanoparticles for a whole range of diseases and with CEO Timm Jessen at the helm. He told me the story of […]

November 15, 2017 - 4 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us